AI Article Synopsis
Article Abstract
According to several reports, the 10 year incidence of secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after systemic chemotherapy is approximately 1.5%. The cumulative risk increases by 0.25--1% for the first 8 years after treatment. We have reported only 6 cases of hematological malignancies (0.3%) after breast cancer chemotherapy in our institute. We detected 2 cases of secondary AML and 1 case of MDS, 19, 52 and 12 months, respectively, after systemic chemotherapy for breast cancer. Published data on the occurrence of secondary hematological malignancies other than AML or MDS in this setting are scarce. We encountered diffuse large B-cell lymphoma, angioimmunoblastic lymphoma and mantle cell lymphoma as secondary hematological malignancies after systemic chemotherapy for breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190500125705 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances of signal transducer and activator of transcription 3 inhibitors in acute myeloid leukemia (Review).
Oncol Lett
March 2025
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China.
Signal transducer and activator of transcription 3 (STAT3), a crucial transcription factor, exerts a notable influence by hyperactivating or acquiring functional mutations in the occurrence and progression of cancers. Hyperactive STAT3 is also implicated in a range of hematopoietic malignancies, especially acute myeloid leukemia (AML). The function of STAT3 is associated with the phosphorylated parallel dimer structure, enabling them to stimulate the transcription of specific genes.
View Article and Find Full Text PDFFever of Unknown Origin: A Rare Presentation of Parathyroid Carcinoma.
Cureus
December 2024
General Medicine, All India Institute of Medical Sciences, Nagpur, Nagpur, IND.
Fever of unknown origin (FUO) can be a common manifestation of multiple disease processes like infections, hematological & solid organ malignancies, autoimmune disorders, and autoinflammatory diseases. Endocrine causes of FUO are rare but should be considered in differential diagnosis. We present a case of a 35-year-old female with prolonged on-and-off fever and intermittent vomiting for nine months, where extensive workups for chronic infections, malignancy, and autoimmune conditions initially yielded no definitive diagnosis.
View Article and Find Full Text PDFCritically ill adult patients with acute leukemia: a systematic review and meta-analysis.
Ann Intensive Care
January 2025
Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Paris University, 1 Avenue Claude Vellefaux, Paris, 75010, France.
Background: To describe the use of life-sustaining therapies and mortality in patients with acute leukemia admitted to the intensive care unit (ICU).
Methods: The PubMed database was searched from January 1st, 2000 to July 1st, 2023. All studies including adult critically ill patients with acute leukemia were included.
Predictive risk model of mild cognitive impairment in patients with malignant haematological diseases after haematopoietic stem cell transplantation.
Support Care Cancer
January 2025
School of Nursing, Nanjing Medical University, Nanjing, Jiangsu, China.
Objective: This study is to develop and validate a robust risk prediction model for mild cognitive impairment (MCI) in patients with malignant haematological diseases after haematopoietic stem cell transplantation (HSCT).
Methods: In this study, we analysed the clinical data of the included patients. Logistic regression analysis was used to identify independent risk factors for cognitive impairment after HSCT in patients with malignant haematological diseases, and a risk prediction model was constructed.
TP53 Mutations are Associated with CD19 Negative Relapse and Inferior Outcomes after Blinatumomab in Adults with ALL.
Blood Adv
January 2025
City of Hope Medical Center, Duarte, California, United States.
Despite the success of the CD19xCD3 T cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD) relapse. To understand the impact of leukemia genetics on outcomes, we reviewed 267 adult patients with B-ALL treated with blinatumomab and used next generation sequencing to identify molecular alterations. Patients received blinatumomab for relapsed/refractory (R/R) disease (n=150), minimal residual disease (MRD+) (n=88), upfront as induction (n=10), or as consolidation in MRD- state (n=19).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!